Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Everything about that website is United states. Why do you think it is Canada. I think it is U.S. interesting
Odds are not even a common sensical question here. So you are saying private companies are not viable without a ticker symbol. you don't need a ticker symbol to be viable. GLTU
Why do you think they would lose as a company?
We both know that is not part of the equation since they did it in October. They need to get off the pot and get this party started. We all want it yesterday no matter what part of the fence we are on. Its all about patience, we all know that. Cannot implement the business plan if you cannot get out of the blocks. we wait.
Great if true. But that is all if you can believe a damn word they say. They could not put the info out to thw world timely. Have not been forthcoming or transparent in the past. They have many things to hide in my estimation.
BC FIRM TO START COVID-19 HUMAN TRIALS IN S.KOREA
published by asingh on Tue, 05/05/2020 - 19:26
By Mata Press Service
As it becomes increasingly clear that even when the COVID-19 pandemic is over, it may not really be over, researchers at a Vancouver-based pharmaceutical development company are not waiting for answers. They are working to find it.
“The sobering truth about the COVID-19 virus is not if you will survive it. It is how healthy your lungs will be after you recover,” notes Christopher J. Moreau, CEO of Vancouver-based Algernon Pharmaceuticals Inc. His company has just been approved to conduct human trials in South Korea on its re-purposed drug, NP-120 (Ifenprodil) that shows promise to protect the lungs from the COVID-19 virus.
Algernon has also received a ‘No Objection Letter from Health Canada’ to proceed with a multinational clinical trial to determine if Ifenprodil can reduce the number of COVID-19 diagnosed patients from progressing to mechanical ventilation with intubation and death.
Research around the world suggests that “once coronavirus patients are placed on a ventilator, they will probably need to stay on it for weeks” and “the longer patients remain on a breathing machine, the more likely they are to die” or sustain lasting lung damage.
Critical-care doctors are also reporting that those who make it out of the ICU after a long stint on a ventilator are more at risk to develop Pulmonary Fibrosis (PF), a condition where lung tissue hardens, and the organ does not function properly.
“This first human trial in South Korea of Ifenprodil in COVID-19 patients is a major step forward with Algernon’s new acute lung injury clinical research program,” said Moreau.
Ifenprodil is a generic neurological drug originally developed in the 1970’s by global health giant, Sanofi, and approved for use in South Korea and Japan. In a recent animal study for H5N1, the world’s most lethal flu, Ifenprodil reduced mortality by 40 per cent and reduced acute lung injury and inflammation in lung tissue. H5N1 has a mortality rate of greater than 50 per cent.
“If Ifenprodil performs this way in an animal study for H5N1, we should see a similar result in humans that have COVID-19,” said Moreau.
“There is a sound basis for thinking that Ifenprodil may be effective in patients with severe pneumonia caused by COVID-19 as there have been some promising results in animal studies involving H5N1 influenza,” said John Moller, chief executive officer of Novotech, a contract research organization, which has been instrumental in the success of over a thousand clinical trials for biotechnology companies.
This month, in South Korea, Algernon will begin its 40-patient, four-week trial, designed to test the re-purposed drug NP-120 (Ifenprodil) in COVID-19 infected patients with severe pneumonia.
The Lead Principal Investigator in South Korea is Dr. Dong Sik Jung, also a professor in the Division of Infectious Disease of Dong-A University Hospital, Busan. Enrollment of the first Korean patients in the Phase 2 clinical trial is expected to begin on May 8.
In Canada the stage is set for Algernon to proceed with a NP-120 (Ifenprodil) COVID-19 Phase 2b/3 multinational clinical trial. The same study protocol is being prepared for submission to the U.S. FDA and Australian regulatory authorities.
So what. neither has some of the other CE stocks that have recently gone pink current and realized monstrous gains. The key difference is when the filings start. GLTU.
Name one of them that has repented the way this company has. Watch for it. And they still climbed in percentages well into the thousands and tens of thousands. Who cares where they went afterward. the initial result is still
BBBBBBBBBBBBBBOOOOOOOOOOOOOOOOOOOOOMMMMMMMMMMMMMMMMMMMM!!!!!!!!!!!
Oh my if, and, or when this goes back to pink.
Wrong Again. Geesh. Gauranteed to have an end result whatever that result is.
WRONG. Please explain, why they run so hard and normal every day pinks do not. Because of the unbelievably great track records of the companies coming off greys with no or little reporting, obscene financials and no business plan? What a bleeping. joke. The evidence is the PERCENTAGES!!!
bbbbbbbbbaaaaaaaaaaaaaaaahhhhhhhhhhhhaaaaaaaaaaaaaaaaaaahhhhhhhhhhaaaaaaaaaa
There are MANY that are 100% sure that this supposed short position is non existent.
Why?
Because there’s absolutely NO EVIDENCE of it.
Yes. And in all the cases that it never happened, There was no evidence of it either, until there was EVIDENCE. LMAO.
Thats the whole problem, they are riding this out as long as they can because they don't know what the he$$ to do if they are forced to allow this to go back to pink. IMO, if they do not it would be the ultimate travesty.
I totally agree with this post. Absolutely on point and hits the mark.
Not to mention this company wants to leave a good impression on their first trip through the tulips
Please explain what exactly is garbage about this ticker based on the last quarterly and the acknowledged share structure. Curious to hear your response.
Totally possible. Really need to see what company is coming in, and if the ta needs to buy back
Its a part of having all basis covered. It makes no sense to me why one cannot ascertain that all items do not have to be realized.
Looking, but in the meantime, this one is definitely authorized.
Currently, the treatment of COVID-19 includes supportive care and treatment of any secondary infections, such as pneumonia. There are no drugs or vaccines approved, but there are now 20 clinical trials authorized in Canada with diagnostic equipment, supportive care and/or treatments for COVID-19.
Health Canada is also in discussions with several sponsors about other potential clinical trials and will update the list below on a regular basis as new trials are available.
Filter items
Showing 1 to 10 of 25 entriesShow entries
Trial Name /Protocol #/control # Title Interventions Authorization holder Authorization date Clinicaltrials.gov Link
(COVID19 PEP RCT - Canada)
2020-6549
(Control # 237355) Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial (COVID19 PEP RCT - Canada) hydroxychloroquine Research Institute of the McGill University Health Centre 2020-03-25 NCT04308668
AGN120-3
Control #238605 A Randomized Open Label Phase 2/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Confirmed COVID-19 Infected Hospitalized Patients. NP-120 (Ifenprodil) Algernon Pharmaceuticals 2020-04-29
Perhaps you can locate for me, any covid 19 trials in Korea? I cannot seem to find them
Not good news, but it will probably help to complete our human trials in S. Korea.
As of May 9, the country confirmed 18 new coronavirus cases — the first time in five days that the number jumped above 10.
Thanks for saving me Jake. I owe you one. LOL.
Would be nice to be the volume start before price and to see the filings all drop first thing Monday morning. It has been a long time coming.
Fantastic, Wouldn't know what to do with out the intelligent comedy. lol.
they can see through the new alias as well i suppose.
predict what, nothings any different than the last post.
been adding more over and over again. you should have over 100 million shares by now, unless your buying 1000 shares everytime you say it, just saying. lol.
I ride with those same words. onward.
Gee, that means we get another press release this week. wonder if it will be real or we will be acquiring a sms company from enrique iglesias. lol.
ok. not funny.
Cool. The experts will figure it out! LOL.
Who is debating. I merely gave my formulated opinion which is emphatically what you just did yourself. I have an opinion, thats it. I am not here to debate. We are living in a whole different world right now. What is the norm, is no longer the new norm. We are on the same side. Not embellished in the la la world known as great.
You are correct. not at the moment, but due to the nature of the beast, if the submission is approved and the trial gives us that keyword Data, as more and more people are effected by the serious strands of covid as well as the current need for a better option for the 2, it will, also IMHO, need to be accelerated just because. All opinion at this juncture, but the necessity is there and so far merited.
Do not know what article you were looking at but, the article I saw had Abcellera getting 175 MIl. (eliLilly). no worries. There is still room for another 175 mil for a company called Algernon.
Great post, but I would beg to differ on the timeline for the fibrosis/chronic cough analogy. JMHO, but i believe they become just as necessary to fasttrack as they are both in direct correlation to the virus. Virus causes chronic cough and eventually leads to fibrosis for those that recover and end up with lung issues. I believe this drug has the opportunity to help a multifaceted multiple branches of the tree of quality of life before, during and after the virus, influenza in general, and with quality of life for pulmonary fibrosis on a wide spectrum. Maybe i am overly excited, but their are multiple possibilities for just this one drug which is not their only drug moving forward. Can be a game changer with tributaries. AGNPF$$$$> GLTA
I second that emotion. It may take some time, but if this is the case what kaboomage will come. T/A's got some splaining to do...
yes. check out ambd the other day. No updated fins since 2006. just incredible the travesty that continues here.
Nothing has changed here. Agendas have changed. Imho, true colors come out sometimes. Not one morsel is any different than before. To me, it just keeps getting better. It will never be about me, me, me. The data is the only indicator we need to define which way this goes. The good thing is, this drug has a multitude of opportunities to make a difference in a variety of health issues. Just got to have that data. Until then, just like every other stock down here, the tree will get shaken repeatedly.
No, you are correct, but include vice versa as well.
Looking good, will be an emphatic update after this endless patience for perserverance.
All the way around. Wish i could add more. Still waiting for impending news hopefully.
Funny enough, I was thinking that exact same scenario with the same price.